Lasofoxifene Tartrate CAS 190791-29-8 Chiral Tsabta ≥99.0% Tsarkake

Lasofoxifene Tartrate CAS 190791-29-8 Chiral Tsafta ≥99.0% Tsafta ≥98.0% (HPLC) API Babban Tsabta

Takaitaccen Bayani:

Sunan Chemical: Lasofoxifene Tartrate

Saukewa: 190791-29

Bayyanar: Fari zuwa Kashe-fari foda

Tsaftar Chiral: ≥99.0%Tsafta: ≥98.0% (HPLC)

A cikin lura da Postmenopausal Osteoporosis

API High Quality, Kasuwancin Kasuwanci

Inquiry: alvin@ruifuchem.com

Aika mana imel

Cikakken Bayani

Samfura masu dangantaka

Tags samfurin

Bayani:

Samar da Mai ƙira tare da Tsaftataccen Tsafta da Tsayayyen inganci
Sunan Chemical: Lasofoxifene Tartrate
Saukewa: 190791-29
Lasofoxifene Tartrate (CAS: 190791-29-8) a cikin maganin Osteoporosis na Postmenopausal

Abubuwan Sinadarai:

Sunan Sinadari	Lasofoxifene Tartrate
Makamantu	(5R,6S) -5,6,7,8-Tetrahydro-6-phenyl-5-[4-[2- (1-pyrrolidinyl) ethoxy] phenyl] -2-naphthalenol Tartrate Oporia
Lambar CAS	190791-29-8
Lambar CAT	RF-API20
Matsayin Hannun jari	A Hannun jari, Ma'aunin Samfuran Har zuwa Daruruwan Kilogram
Tsarin kwayoyin halitta	Saukewa: C28H31NO2.ClH
Nauyin Kwayoyin Halitta	450.019
Alamar	Ruifu Chemical

Ƙayyadaddun bayanai:

Abu	Ƙayyadaddun bayanai
Bayyanar	Fari zuwa Kashe-Farin Foda
Danshi (KF)	≤0.50%
Karfe masu nauyi	≤20ppm
Chiral Tsafta	≥99.0%
Tsarkake / Hanyar Bincike	≥98.0% (HPLC)
Asara akan bushewa	≤0.50%
Ragowa akan Ignition	≤0.50%
Matsayin Gwaji	Pharmacopoeia na kasar Sin (CP);Matsayin Kasuwanci
Amfani	Sinadarin Magunguna Mai Aiki (API);Osteoporosis na postmenopausal

Kunshin & Ajiya:

Kunshin: Bottle, Aluminum tsare jakar, Kwali drum, 25kg / Drum, ko bisa ga abokin ciniki ta bukata.

Yanayin Ajiya:Ajiye a cikin kwantena da aka rufe a wuri mai sanyi da bushe;Kare daga haske, danshi da kamuwa da kwari.

Amfani:

FAQ:

Aikace-aikace:

Shanghai Ruifu Chemical Co., Ltd. shine babban masana'anta kuma mai samar da Lasofoxifene Tartrate (CAS: 190791-29-8) tare da babban inganci.
Lasofoxifene Tartrate shine ƙarni na uku, mai zaɓin mai karɓar isrogen mai karɓa (SERM) mara amfani.Yana zaɓin ɗaure ga ɗan adam ERalpha tare da ƙimar IC50 na 1.5 nM kuma yana hana asarar kashi a cikin berayen ovariectomized.A cikin nazarin asibiti na postmenopausal osteoporosis, 0.5 mg / day lasofoxifene an hade shi da rage hadarin da ba a yi ba da kuma vertebral fractures, ER-positive ciwon nono, cututtuka na zuciya da jijiyoyin jini, da bugun jini amma ya kara hadarin venous thromboembolic abubuwan da suka faru.Hakanan an nuna Lasofoxifene don yin aiki azaman agonist mai juzu'i a mai karɓar CB2 cannabinoid, yana nuna yiwuwar sake dawo da shi azaman magani don alamun da CB2 ke da manufa.